Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] SK Hynix (000660) – New Facility Investment / 2024-04-24

Posted on April 24, 2024July 29, 2026 By K-STOCK Editor No Comments on [Disclosure] SK Hynix (000660) – New Facility Investment / 2024-04-24

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

SK Hynix has approved a new facility investment of approximately KRW 5.296T to construct the Cheongju M15X fab, aimed at proactively responding to semiconductor demand and expanding next-generation DRAM production capacity.

📊 Key Disclosure Contents & Financial Figures

  • Investment Type: Facility Expansion (Construction of Cheongju M15X)
  • Investment Amount: KRW 5,296,200,000,000 (~KRW 5.296T)
  • Ratio to Equity: 9.90% (Based on recent fiscal year-end consolidated equity of KRW 53,503,752,397,611)
  • Large-Scale Corporation Status: Applicable
  • Investment Purpose: Expansion of next-generation DRAM production capacity to proactively respond to semiconductor demand
  • Investment Period: April 24, 2024 – October 30, 2026
  • Board Resolution Date: April 24, 2024 (All 6 outside directors present)
  • Other Important Notes: The investment amount and period may vary based on project progress and market conditions. The scheduled end date is an estimate.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Investment Execution and Construction Timeline

This disclosure details the formal commitment to construct the Cheongju M15X fab in order to meet growing next-generation DRAM demand. Tracking whether the planned investment amount (approx. KRW 5.3T) and completion timeline (October 30, 2026) are adjusted due to shifts in industry conditions or project execution is important for monitoring the company’s major CAPEX rollout. Relevant details can be verified in subsequent disclosures and periodic reports (Quarterly, Half-Yearly, and Annual Reports).

📢 Disclaimer & Source Information

Source: This content was structured and newly generated based on official filing data from the Financial Supervisory Service (DART).

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Samsung Biologics (207940) – Provisional Performance (Consolidated Financial Results) / 2024-04-24
Next Post: [Disclosure] SK Hynix (000660) – Decision on Cash / Property Dividend / 2024-04-24

Related Posts

[Disclosure] SK Square (402340) – Correction of Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2026-03-03 Semiconductors
[Disclosure] Jusung Engineering (036930) – Results of General Shareholders’ Meeting / 2026-03-26 Semiconductors
[Disclosure] Hanwha Aerospace (012450) – Investor Relations (IR) Event Notice for Q2 2024 Performance (Domestic Institutional Investors) Disclosures
[Disclosure] SK hynix (000660) – Other Disclosure (Notice of Reference Price for Interim (Quarterly) Ex-Dividend) / 2025-08-27 Semiconductors
[Disclosure] Samsung Electronics (005930) – Decision on Convening Annual General Meeting of Shareholders / 2025-02-18 Disclosures
[Disclosure] Hanwha Ocean (042660) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-02-18 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme